Evidence map›Paper›PMID 38694878›Full record

ArticleEuropean urology open science2024

Suitability of the MP1000 Platform for Robot-assisted Prostatectomy: A Prospective Randomised Controlled Trial.

Shaoxi Niu, Liyan Ao, Yu Gao, Fangjian Zhou, Wang He, Jin Tao, Shengjie Guo, Baojun Wang, Xing Ai, Hongzhao Li and 4 more

Abstract read
In one paragraph

Article in European urology open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shaoxi NiuDepartment of Urology, Third Medical Centre, Chinese PLA General Hospital, Beijing 100039, China.
Liyan AoDepartment of Urology, Third Medical Centre, Chinese PLA General Hospital, Beijing 100039, China.
Yu GaoDepartment of Urology, Third Medical Centre, Chinese PLA General Hospital, Beijing 100039, China.
Fangjian ZhouDepartment of Urology, Sun Yat-sen University Cancer Centre, Guangzhou, China.
Wang HeDepartment of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Jin TaoDepartment of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shengjie GuoDepartment of Urology, Sun Yat-sen University Cancer Centre, Guangzhou, China.
Baojun WangDepartment of Urology, Third Medical Centre, Chinese PLA General Hospital, Beijing 100039, China.
Xing AiDepartment of Urology, Third Medical Centre, Chinese PLA General Hospital, Beijing 100039, China.
Hongzhao LiDepartment of Urology, Third Medical Centre, Chinese PLA General Hospital, Beijing 100039, China.
Xin MaDepartment of Urology, Third Medical Centre, Chinese PLA General Hospital, Beijing 100039, China.
Xuepei ZhangDepartment of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jian HuangDepartment of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Xu ZhangDepartment of Urology, Third Medical Centre, Chinese PLA General Hospital, Beijing 100039, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: Robot-assisted radical prostatectomy (RARP) is widely used because of the many advantages of a robotic approach. The da Vinci Si robot is one of the most commonly used surgical robot systems, but it may be associated with higher costs owing to the use of consumable surgical supplies. Our aim was to conduct a preliminary investigation of the capability of the MP1000 system for RARP. Methods: In this prospective, multicentre, single-blinded study, we randomly assigned 42 patients scheduled to undergo RARP between April and September 2021 to a da Vinci Si group (control) or an MP1000 group (intervention). Patients underwent RARP performed using the assigned robotic system and were followed up at 3-mo intervals. The primary outcome was the rate of conversion to open/laparoscopic surgery. Secondary outcomes were installation and operation times, intraoperative blood loss, postoperative surgical margin status, hospital stay, incontinence, complications, safety indicators, and surgeon ergonomics. Key findings and limitations: All procedures were successfully completed without conversion to open/laparascopic surgery or major complications. Secondary outcomes, including oncological and ergonomic indicators, did not differ significantly between the groups over the study period. One patient in the control group experienced dysuria (Clavien-Dindo grade 3). No patients had incontinence at 3 mo. A limitation of the study is the small sample size. Conclusions and clinical implications: RARP with the MP1000 system is feasible, safe, and effective in the management of localised prostate cancer. Patient summary: We assessed the effectiveness and safety of the new MP1000 robot system for robot-assisted removal of the prostate in comparison to the da Vinci Si robot. We found no difference in effectiveness or safety among 42 patients with prostate cancer who were assigned randomly to one of the two systems. We conclude that the MP1000 is a suitable robot for this surgery.

Indexed as

da Vinci Si robotMP1000 robotProstate cancerRobot-assisted radical prostatectomyRobotic surgery

Identifiers

PMID38694878
PMCPMC11058071

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.